David Hoye to Join SK3 Group (OTC Pink: SKTO) Board of Directors
April 15 2014 - 9:30AM
Marketwired
David Hoye to Join SK3 Group (OTC Pink: SKTO) Board of Directors
LOS ANGELES, CA--(Marketwired - Apr 15, 2014) - David Hoye has
been appointed to the Board of Directors of SK3 Group, Inc. (OTC
Pink: SKTO) (PINKSHEETS: SKTO). Hoye is co-founder of Berkeley
Bio-Organic Research Laboratories, which was acquired in April of
last year.
"I am honored to be asked to take this position," said Hoye.
"Over the past year that my group has been working with SK3 Group,
I have been very impressed with the skill, competence, and
compassion for patients expressed by my new partners. It seems that
we now have a perfect union of business and financial acumen
combined with science and compassion. I could not have asked for a
better situation when I first associated with SK3 Group, and being
asked to take an increased role in the overall direction we will be
taking as we pioneer this new sector is something that I
cherish."
"We are very pleased to have David take an official position on
the Board of Directors of our company," said Artemus Mayor,
President of SK3 Group, Inc. "David's Berkeley Bio-Organic Research
Laboratories was an early acquisition made by SK3 Group after
entering the medical marijuana sector. As a result of his
expertise, knowledge, and experience, we now have a rapidly
expanding line of unique, industry-leading cannabis/hemp-based
products and technology that will play an important role in this
new sector of medicine. By taking an official position on the Board
of SK3 Group, parent company of Berkeley Bio, David will help guide
us through the many intricacies of this fascinating and beneficial
emerging new world of business and healthcare."
"David's accomplishments in this world are legendary. His book,
Cannabis Alchemy, published in 1972, has sold 100,000 copies and
was the first scientific book on cannabis technology presented from
a consumer's point of view. It introduced the cannabis culture to
cannabidiol (CBD), cannabis oil, isomerization, extraction, resin
separation, and refinement to pure THC. Amongst many other
significant accomplishments, David opened the first new legal
dispensary in San Francisco after the passage of Proposition 215,
he and his wife Mary Ann founded and run a collective which treats
dozens of cancer patients at no cost, and David was a co-founder of
Berkeley Bio-Organic Research Laboratories, which has made several
groundbreaking discoveries resulting in exciting and beneficial new
cannabis/hemp-based healthcare products."
"David's achievements over nearly five decades in cannabis
science have made him renowned in the world of cannabis culture,"
Mayor continued. "His experience, knowledge, and contacts in this
arena will be of great benefit as we determine the best path to
take in order to provide solid value to our shareholders, and the
substantial healthcare benefits of this amazing medicinal plant to
the patients who utilize our technology and products."
About SKTO SK3 Group, Inc. is a healthcare logistics and
fulfillment consultancy focused on the delivery of alternative care
and medicine. With seasoned management, breakthrough technology and
best practices, SK3 Group brings standardization and transparency
to this rapidly growing segment of the alternative care field.
FDA Statement The statements in this document have not been
evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Medical Greens Investor Relations
investors@medicalgreens.com
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Aug 2024 to Sep 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Sep 2023 to Sep 2024